IL1RL1 and chronic obstructive pulmonary disease: Astegolimab targets Il1rl1/ST2 and has been tested in a randomized, placebo-controlled phase 2a trial in patients with moderate/very severe COPD who were on triple therapy with a SAMA/LAMA/inhaled corticosteroid [70].